Share this article
Share this article
NEW YORK, July 14, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Axsome and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On July 14, 2021, Axsome disclosed in a filing with the U.S. Securities and Exchange Commission "that it has been notified by the U.S. Food and Drug Administration (the 'FDA') that the FDA is rescinding the Company's Breakthrough Therapy Designation for its AXS-12 product candidate for the treatment of cataplexy in narcolepsy, due to the FDA approving an additional drug product for the treatment of cataplexy in narcolepsy subsequent to granting AXS-12 Breakthrough Therapy Designation."